Compass Therapeutics annual return on equity
2019
2021
2022
2023
2024
2025
Compass Therapeutics Return on Equity (ROE) Growth & History (CMPX)
Compass Therapeutics's return on equity was −41.29% for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −41.29% | −5.22 pp |
| 2024 | 2024-12-31 | −36.07% | −10.33 pp |
| 2023 | 2023-12-31 | −25.74% | −1.36 pp |
| 2022 | 2022-12-31 | −24.38% | +66.92 pp |
| 2021 | 2021-12-31 | −91.30% | — |
| 2019 · Dec 31 | 2019-12-31 | −620.63% | — |
Compass Therapeutics quarterly return on equity
Q2.21
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −14.27% | +5.27 pp |
| Q1 2026 | 2026-03-31 | −9.56% | +4.57 pp |
| Q4 2025 | 2025-12-31 | −7.73% | +3.67 pp |
| Q3 2025 | 2025-09-30 | −9.42% | −2.05 pp |
| Q2 2025 | 2025-06-30 | −19.54% | −10.91 pp |
| Q1 2025 | 2025-03-31 | −14.12% | −7.07 pp |
| Q4 2024 | 2024-12-31 | −11.40% | −2.71 pp |
| Q3 2024 | 2024-09-30 | −7.37% | −1.30 pp |
| Q2 2024 | 2024-06-30 | −8.63% | −2.06 pp |
| Q1 2024 | 2024-03-31 | −7.06% | −2.67 pp |
| Q4 2023 | 2023-12-31 | −8.69% | −0.91 pp |
| Q3 2023 | 2023-09-30 | −6.07% | +3.78 pp |
| Q2 2023 | 2023-06-30 | −6.57% | −0.07 pp |
| Q1 2023 | 2023-03-31 | −4.39% | +0.83 pp |
| Q4 2022 | 2022-12-31 | −7.79% | — |
| Q3 2022 | 2022-09-30 | −9.85% | +12.79 pp |
| Q2 2022 | 2022-06-30 | −6.50% | +172.52 pp |
| Q1 2022 | 2022-03-31 | −5.22% | +15.00 pp |
| Q3 2021 | 2021-09-30 | −22.65% | −4.45 pp |
| Q2 2021 · Jun 30 | 2021-06-30 | −179.01% | — |
| Q1 2021 · Mar 31 | 2021-03-31 | −20.22% | — |
| Q4 2020 | 2020-12-31 | −19.24% | — |
| Q2 2021 · Sep 30 | 2020-09-30 | −18.20% | — |
Compass Therapeutics return on equity trends
Between the periods ended 2019-12-31 and 2025-12-31, Compass Therapeutics's return on equity increased from −620.63% to −41.29%, a change of +579.33 percentage points. The latest reported quarter, Q2 2026, shows −14.27%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗